Effect of BI 1181181 on PK of Probe Drugs

Phase 1, randomised, open-label trial of BI 1181181 in Alzheimer's disease (AD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point of midazolam at 24 hours, Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point of omeprazole at 24 hours and 6 more. Planned start Mar 2015; status: withdrawn.